Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease

Sezen D., Verma V., He K., Abana C. O., Barsoumian H., Ning M. S., ...More

SEMINARS IN RADIATION ONCOLOGY, vol.31, no.3, pp.217-226, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 31 Issue: 3
  • Publication Date: 2021
  • Doi Number: 10.1016/j.semradonc.2021.02.005
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Page Numbers: pp.217-226
  • Hacettepe University Affiliated: Yes


Metastatic cancer is inherently heterogeneous, and patients with metastatic disease can experience vastly different oncologic outcomes depending on several patient-and disease specific characteristics. Designing trials for such a diverse population is challenging yet necessary to improve treatment outcomes for metastatic-previously thought to be incurable-disease. Here we review core considerations for designing and conducting clinical trials involving radiation therapy and immunotherapy for patients with metastatic cancer. Semin Radiat Oncol 31:217-226 Published by Elsevier Inc.